L&C Bio Co., Ltd

KOSDAQ 290650.KQ

L&C Bio Co., Ltd Capital Expenditure for the year ending December 31, 2023: USD -19.19 M

L&C Bio Co., Ltd Capital Expenditure is USD -19.19 M for the year ending December 31, 2023, a 35.58% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

L&C Bio Co., Ltd Capital Expenditure for the year ending December 31, 2022 was USD -29.79 M, a -211.40% change year over year.
L&C Bio Co., Ltd Capital Expenditure for the year ending December 31, 2021 was USD -9.57 M, a -241.08% change year over year.
L&C Bio Co., Ltd Capital Expenditure for the year ending December 31, 2020 was USD -2.80 M, a -61.95% change year over year.
L&C Bio Co., Ltd Capital Expenditure for the year ending December 31, 2019 was USD -1.73 M, a 59.38% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

KOSDAQ: 290650.KQ

L&C Bio Co., Ltd

CEO	Mr. Chul Lee Whan
IPO Date	Nov. 1, 2018
Location	South Korea
Headquarters	Suntechcity
Employees	122
Sector	Healthcare
Industries Biotechnology

Description

L&C BIO Co., Ltd. operates as a research and development company in tissue regeneration medicine. It offers human tissue, medical device, and cosmetics products. The company was founded in 2011 and is headquartered in Seongnam, South Korea.

Key trends

Past 5 years